NRx Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business Update

Enrollment continues in the Phase 2b/3 clinical trial evaluating NRX-101 in Suicidal Treatment-Resistant Bipolar Depression; data expected in 4Q 2023National educational campaign launched to further... | May 16, 2023

Related Keywords

Chicago ,Illinois ,United States ,Massachusetts ,Stephen Willard ,Andrew Nierenberg ,Source Nrx Pharmaceuticals Inc ,Prnewswire Nrx Pharmaceuticals Inc ,Nasdaq ,University Of Texas ,Nrx Pharmaceuticals ,Company As Treatment ,Dauton Family Center ,Nrxp Nrx Pharmaceuticals ,Northwestern University Chicago ,Nrx Pharmaceuticals Inc ,Drug Administration ,Suicidal Treatment Resistant Bipolar Depression ,Therapy Designation ,Chief Executive Officer ,Breakthrough Therapy Designation ,Quarter Clinical ,Fast Track Designation ,Special Protocol Agreement ,Biomarker Letter ,Treatment Resistant Bipolar Depression ,Data Safety Monitoring Board ,Massachusetts General Hospital ,Bipolar Treatment Innovation ,Principal Investigator ,Northwestern University ,Post Traumatic Stress Disorder ,Streeterville Capital ,First Quarter Ended March ,Severe Bipolar Depression ,Acute Suicidal Ideation ,Securities Litigation Reform Act ,Earnout Cash ,Nc Stock Exchange ,News ,Information ,Press Release ,Enrollment ,Ontinues ,N ,The ,Hase ,Linical ,Trial ,Valuating ,Suicidal ,Bipolar ,Data ,Xpected ,Q ,023national ,Educational ,Campaign ,Aunched ,O Nrxp Us6294441000 ,